EC closes two pharma investigations, but national authorities continue antitrust scrutiny *

European Union - June 12 2012
In early March, the EC announced in quick succession the closure of investigations into alleged anti-competitive practices by AstraZeneca and GlaxoSmithKline, among others, that it considered may have delayed the entry of generic drugs onto the market.

EC puts competition scrutiny of parallel trade back on the agenda *

European Union - June 12 2012
Recent comments made by EC Vice President Joaquín Almunia suggest that the EC may be turning its attention back to parallel trade issues in the pharmaceutical sector.

OECD Competition Committee publishes report on generic pharmaceuticals policy roundtable *

Global - December 2 2010
On 3 September 2010, the Competition Committee of the Organization for Economic Cooperation and Development (OECD) published a summary of its October 2009 roundtable discussion on generic pharmaceuticals.

AstraZeneca appeals judgment of the General Court on abuse of dominance *

European Union - December 2 2010
On 22 October 2010, details were published of AstraZeneca's appeal before the Court of Justice of the European Union (CJEU) of a judgment of the General Court, which had largely upheld the European Commission's 2005 decision finding that AstraZeneca had abused a dominant position.